David Charles Lubner insider trades

Open-market stock purchases and sales by David Charles Lubner, Director at Braveheart Bio, Inc, from SEC Form 4 filings since Mar 25, 2013.

Track record: 100% of 1 scored buy are up 5% or more since purchase, averaging +17%.

Recent trades

DateStockTradeValue
Aug 7, 2026BRVE Braveheart Bio, IncBought$1M
Aug 5, 2026BRVE Braveheart Bio, IncBought (not open market)—
Jun 5, 2026DYN Dyne Therapeutics, IncBought (not open market)—
Jun 2, 2026CBIO Crescent Biopharma, IncBought (not open market)—
Apr 28, 2026ACLX Arcellx, IncSold (not open market)—
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$93.1K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$373K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$212K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$923K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$435K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$411K
Apr 28, 2026ACLX Arcellx, IncSold (not open market)$584K
Apr 24, 2026DYN Dyne Therapeutics, IncSold (not open market)—
Jan 20, 2026ACLX Arcellx, IncSold$450K
Jan 20, 2026ACLX Arcellx, IncBought (not open market)—

Companies traded

  • BRVE Braveheart Bio, Inc: 1 buy, last Aug 7, 2026
  • DYN Dyne Therapeutics, Inc: 1 buy, last Jun 5, 2026
  • CBIO Crescent Biopharma, Inc: other filings, last Jun 2, 2026
  • ACLX Arcellx, Inc: 1 sale, last Apr 28, 2026
  • CRGX CARGO Therapeutics, Inc: other filings, last Aug 19, 2025
  • VOR Vor Biopharma Inc: other filings, last May 22, 2025
  • PNT POINT Biopharma Global Inc: 1 buy, last Dec 27, 2023
  • GMTX Gemini Therapeutics, Inc /DE: other filings, last Oct 4, 2021
  • RARX Ra Pharmaceuticals, Inc: other filings, last Apr 2, 2020
  • NITE Nightstar Therapeutics plc: other filings, last Jun 7, 2019
  • TTPH Tetraphase Pharmaceuticals Inc: 10 sales, last Aug 14, 2015

Get free alerts when David Charles Lubner files a new trade →